Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
01:01pm, Wednesday, 10'th Jun 2026
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Novo Nordisk faces off in court with South African weight-loss drug compounder
06:16am, Wednesday, 10'th Jun 2026
Danish drugmaker Novo Nordisk is heading to court in South Africa on Wednesday to try to halt the sale of unapproved copies of semaglutide, the key ingredient in its blockbuster weight-loss and dia
Novo Nordisk CEO: '80% of Wegovy pill customers' have never taken a GLP-1 before
02:42pm, Tuesday, 09'th Jun 2026
At the American Diabetes Association's 2026 Scientific Sessions, CNBC's Angelica Peebles sat down with Novo Nordisk CEO Mike Doustdar to discuss the launch of the Wegovy pill and how it became the bes
Novo Nordisk CEO: 'Common sense' should drive seniors on Medicare to opt for Wegovy
02:40pm, Tuesday, 09'th Jun 2026
At the American Diabetes Association's 2026 Scientific Sessions, CNBC's Angelica Peebles sat down with Novo Nordisk CEO Mike Doustdar to discuss the July 1 start date of GLP-1 coverage for seniors on
Novo Nordisk CEO: We are a cardiometabolic powerhouse
01:30pm, Tuesday, 09'th Jun 2026
At the American Diabetes Association's 2026 Scientific Sessions, CNBC's Angelica Peebles sat down with Novo Nordisk CEO Mike Doustdar to discuss what to expect from Novo's pipeline and strategy in the
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
11:01am, Tuesday, 09'th Jun 2026
Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.
Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
09:20am, Tuesday, 09'th Jun 2026
More employers and health plans are balking at paying for costly GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and the treatment of obesity, according to a new report.
Use of GLP-1 drugs early in pregnancy should not cause alarm
05:05pm, Monday, 08'th Jun 2026
Use of GLP-1 drugs for diabetes or obesity early in the first trimester of pregnancy, before a woman realizes she is pregnant, is not a cause for alarm, a large new data analysis suggests.
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.
12:14pm, Monday, 08'th Jun 2026
Zealand Pharma reported a high drop-out rate in a phase III trial of Survodutide, due to undesirable side effects experienced by patients. That's good news for Eli Lilly and Novo Nordisk, which curren
Novo Nordisk Real-World Data Supports Ozempic Against LLY's Mounjaro
12:00pm, Monday, 08'th Jun 2026
NVO says real-world data show Ozempic 2 mg matches Eli Lilly's Mounjaro on glucose control and is linked to a higher likelihood of meaningful weight loss.
Novo Nordisk: The Biggest Healthcare Bargain
11:25am, Monday, 08'th Jun 2026
Novo Nordisk remains a Strong Buy, supported by robust volume growth in GLP-1 products despite recent earnings misses and price compression. NVO's oral Wegovy launch exceeded Street expectations, with
Can Wegovy Pill's Rapid Uptake Give Novo Nordisk an Edge Over LLY?
10:41am, Monday, 08'th Jun 2026
NVO's oral Wegovy launch is off to a blistering start, topping 3 million prescriptions in five months and drawing many first-time GLP-1 users.
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
10:30am, Monday, 08'th Jun 2026
Novo Nordisk and Eli Lilly are introducing GLP-1 pills for obesity, and that competition was on display this weekend at the American Diabetes Association (ADA) Scientific Sessions. CNBC spoke to Novo
Novo Nordisk A/S - share repurchase programme
08:09am, Monday, 08'th Jun 2026
Bagsværd, Denmark, 8 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of
Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch
02:42am, Monday, 08'th Jun 2026
The Danish drugmaker said the pill hit one million prescriptions 12 weeks after reaching U.S. pharmacies and online providers, and reached a further two million prescriptions in the following 10 weeks
